
Cannabis producer Flora Growth Corp. (NASDAQ:FLGC) announced today that its seeking approval from INVIMA, the Colombian FDA, to begin research on their patent-pending, cannabinoid-based product, citing recent studies stating the possibility of cannabinoids to display viral inhibition.
The study will be conducted through Flora’s research division, Flora Pharma, with formulation taking place in its GMP-certified Colombian lab.